NVIDIA Partners with Schrödinger to Further Accelerate Drug Discovery Worldwide
April 12 2021 - 12:19PM
GTC -- NVIDIA today announced a strategic
partnership with Schrödinger that harnesses NVIDIA DGX A100™
systems to further expand the speed and accuracy of Schrödinger’s
computational drug discovery platform and enable rapid, accurate
evaluation of billions of molecules for potential development of
therapeutics.
The companies will optimize Schrödinger’s software platform —
designed to model and predict the properties of novel molecules —
for the NVIDIA DGX SuperPOD™, which is built with NVIDIA DGX A100
systems and NVIDIA InfiniBand HDR networking.
The work includes the physics-based modeling in Schrödinger’s
product suite, as well as support for NVIDIA Clara™ Discovery, a
collection of state-of-the-art AI frameworks, applications and
pre-trained models for the most advanced computational drug
discovery. Additionally, the companies will partner on scientific
and research breakthroughs to further advance physics-based
computing and machine learning for drug discovery.
For each potential drug candidate, Schrödinger routinely
evaluates tens of thousands of molecules with its most
computationally intensive physics-based approaches. This requires
hundreds of thousands of hours of GPU time on high-performance
computers.
Through the collaboration, the entire pharmaceutical industry
comprising over 3,000 companies — from startups to multinationals —
will be able to further accelerate drug discovery at supercomputing
scale. The joint solution will enable companies of all sizes to
simulate molecular combinations with physics and AI to identify and
optimize the most promising compounds for potential therapeutic
use. Pharmaceutical companies can run this research on their own
easy-to-deploy private clouds featuring the Schrödinger platform
running on NVIDIA DGX SuperPOD, which is available to install on
premises or in a colocation facility.
“The predictive modeling built into our platform is designed to
dramatically expand and accelerate the search for high-quality
therapeutic molecules, and NVIDIA is a key technology partner in
this work,” said Patrick Lorton, chief technology officer at
Schrödinger. “Our advanced computational software helps the world’s
biggest pharma companies explore more of the chemical space and
reach high-quality candidates more quickly, with far less compute
cost, than traditional methods. We’re proud to be working with
NVIDIA to make that process run even more smoothly.”
NVIDIA research and engineering teams are working to advance and
optimize the Schrödinger suite to take advantage of the NVIDIA
Ampere architecture and its Multi-Instance GPU technology.
Customers will be able to easily deploy Schrödinger software on a
single DGX system or a cluster of 20 or more to create a DGX
SuperPOD. This allows scaling the Schrödinger platform to dozens of
drug programs and screening and evaluating billions of molecules a
week.
“Computational drug discovery is improving accuracy with
Schrödinger’s advanced combination of simulation with machine
learning,” said Kimberly Powell, vice president of healthcare at
NVIDIA. “Together, we’re giving the pharmaceutical industry a
scientific instrument that delivers super-high-throughput lead
generation to improve and accelerate the success of drug
candidates.”
About NVIDIANVIDIA‘s (NASDAQ: NVDA) invention
of the GPU in 1999 sparked the growth of the PC gaming market and
has redefined modern computer graphics, high performance computing
and artificial intelligence. The company’s pioneering work in
accelerated computing and AI is reshaping trillion-dollar
industries, such as transportation, healthcare and manufacturing,
and fueling the growth of many others. More information at
https://nvidianews.nvidia.com/.
For further information,
contact:Janette CiborowskiNVIDIA
Corporation+1-734-330-8817jciborowski@nvidia.com
Certain statements in this press release including, but not
limited to, statements as to: the benefits and impact of NVIDIA and
Schrödinger partnering and what it will enable; the companies
optimizing Schrödinger’s software platform; the benefits, impact
and performance of our products and technologies; the companies
advancing physics-based computing and machine learning for drug
discovery; the work that goes into evaluating drug candidates; the
collaboration enabling the pharmaceutical industry to accelerate
drug discovery at scale and how they can use this technology; the
availability of the Schrödinger platform; the benefits of
predictive modeling built into the Schrödinger platform;
Schrödinger’s software helping the biggest companies; how NVIDIA is
contributing to Schrödinger’s work and advancing its suite of
products; how customers can deploy Schrödinger software and what it
allows; and how computational drug discovery is improving are
forward-looking statements that are subject to risks and
uncertainties that could cause results to be materially different
than expectations. Important factors that could cause actual
results to differ materially include: global economic conditions;
our reliance on third parties to manufacture, assemble, package and
test our products; the impact of technological development and
competition; development of new products and technologies or
enhancements to our existing product and technologies; market
acceptance of our products or our partners’ products; design,
manufacturing or software defects; changes in consumer preferences
or demands; changes in industry standards and interfaces;
unexpected loss of performance of our products or technologies when
integrated into systems; as well as other factors detailed from
time to time in the most recent reports NVIDIA files with the
Securities and Exchange Commission, or SEC, including, but not
limited to, its annual report on Form 10-K and quarterly reports on
Form 10-Q. Copies of reports filed with the SEC are posted on the
company’s website and are available from NVIDIA without charge.
These forward-looking statements are not guarantees of future
performance and speak only as of the date hereof, and, except as
required by law, NVIDIA disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.© 2021 NVIDIA Corporation. All rights reserved.
NVIDIA, the NVIDIA logo, DGX A100, NVIDIA Clara and NVIDIA DGX
SuperPOD are trademarks and/or registered trademarks of NVIDIA
Corporation in the U.S. and other countries. Other company and
product names may be trademarks of the respective companies with
which they are associated.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/93c4dd86-d822-42cd-85be-0d9355a4d051
NVIDIA (NASDAQ:NVDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
NVIDIA (NASDAQ:NVDA)
Historical Stock Chart
From Apr 2023 to Apr 2024